Related Experiment Video
Updated: Aug 15, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi
Abstract:
The major proteolytic activity of Trypanosoma cruzi is a cathepsin L-like cysteine protease expressed in all stages of the parasite. As an initial step in identifying possible functions of this enzyme in the life cycle of T. cruzi, and examining its potential as a target for rational drug design, two fluoromethyl ketone-derivatized cysteine protease inhibitors were studied for their effects on T. cruzi infection of mammalian cells. Both inhibitors are irreversible substrate analogues with high specificity for cysteine proteases and minimal toxicity to mammalian cells. While micromolar concentrations of inhibitors had some effect on replication of all parasite stages, the most dramatic arrest of parasite replication occurred at the transformation of trypomastigote to amastigote, and also from amastigote to trypomastigote. It is therefore proposed that the enzyme functions in intracellular protein degradation in some stages of T. cruzi, but also in remodeling of the parasite during transformation between stages. Concentrations of inhibitors necessary to interrupt the parasite life cycle had no observable toxicity to macrophages, fibroblasts or epithelial cells in culture. Differential susceptibility of T. cruzi versus host cysteine proteases to fluoromethyl ketone protease inhibitors suggests that inhibition of the T. cruzi cysteine protease is a potential lead for new chemotherapy of Chagas' disease.
Insights
Inhibiting a key cysteine protease in Trypanosoma cruzi, the parasite causing Chagas' disease, halts its replication and transformation. This T. cruzi enzyme is a promising drug target with minimal host cell toxicity.
Area of Science:
- Parasitology
- Molecular Biology
- Drug Discovery
Background:
- Trypanosoma cruzi possesses a major cysteine protease essential for its life cycle.
- This protease is a potential target for developing new Chagas' disease therapies.
Purpose of the Study:
- To investigate the function of the T. cruzi cysteine protease.
- To evaluate cysteine protease inhibitors as potential drug leads for Chagas' disease.
Main Methods:
- Utilized two fluoromethyl ketone-derivatized cysteine protease inhibitors.
- Assessed inhibitor effects on T. cruzi infection and replication in mammalian cells.
Main Results:
- Inhibitors arrested parasite replication, particularly during stage transformations.
- Effective concentrations showed no observable toxicity to host cells (macrophages, fibroblasts, epithelial cells).
Conclusions:
- The T. cruzi cysteine protease is involved in intracellular protein degradation and stage remodeling.
- Targeting this protease offers a potential therapeutic strategy for Chagas' disease with a favorable safety profile.
More Related Videos
Related Concept Videos
American Trypanosomiasis
Anthelminthic Agents
Antiprotozoal Agents

